Improving lifetime performance of turkeys through better gut functionality

In Brief

  • Growing Demand for Animal Protein: The increasing demand for high-quality animal protein necessitates the poultry industry's focus on enhancing turkey performance and health.
  • Rise of Enzyme Supplementation: Enzymes have gained prominence in animal nutrition, aiding in improved digestibility and welfare. Muramidase, a novel enzyme, has been introduced to enhance gut functionality and feed efficiency.
  • Positive Effects in Trials: Two experiments demonstrated muramidase's positive impact on turkey performance. High and step-down doses of muramidase improved body weight, daily gain, feed conversion ratio, and breast meat yield.
  • Improved Gut Functionality: Muramidase's ability to hydrolyze bacterial cell walls' peptidoglycans (PGN) led to better gut functionality, nutrient absorption, and reduced pododermatitis scores, making it a promising addition to turkey diets.

As the demand for high-quality animal protein continues to grow, it is essential for the poultry industry to find ways to improve the performance and health of turkeys. In recent years, the use of enzymes in animal nutrition to improve performance, health, and welfare has increased substantially. Generally, feed enzymes are supplemented to improve the digestibility of dietary nutrients. More recently, another type of feed enzyme, muramidase (Balancius®, dsm-firmenich), has been introduced to support gut functionality and improve feed efficiency. Muramidase is known to hydrolyze peptidoglycans (PGN) of dead bacterial cell walls and improve the performance of broilers in a dose-dependent manner. However, until recently there has been limited information available on the effects of muramidase supplementation in turkeys. This article describes two experiments that were conducted to evaluate the effects of muramidase supplementation in turkeys on performance parameters.

Trial 1

In one study, male B.U.T. 6 turkey poults were fed one of three diets for 126 days. The diets were nutrient adequate and based on soybean meal, wheat, and maize. A group without muramidase supplementation was the control. The treatment groups comprised of a group with high dose of muramidase (45,000 LSU(F)/kg) and a group with a step-down dose of muramidase (45,000 LSU(F)/kg until day 56 and 25,000 LSU(F)/kg from d57-126). The results showed that turkeys fed the high dose muramidase had significantly greater body weight, average daily gain, and improved feed conversion ratio compared to the control group. Similarly, birds fed the step-down dose of muramidase had a final body weight and average daily gain that were intermediate to or equivalent to birds fed the high dose of muramidase. In addition, breast meat yield was significantly greater in turkeys fed muramidase, regardless of the dose, compared to birds fed the control diet. The frequency of pododermatitis score 1 (minor lesions) was significantly greater and score 2 (some lesions) was significantly lower in birds fed muramidase, regardless of dose, compared with those fed the control diet. These findings suggest that muramidase supplementation can improve the performance of turkeys in a dose-dependent manner.

Trial 2

In another study, the efficacy of the microbial muramidase was evaluated on the growth performance of female B.U.T. Premium turkeys from 1-84 days of age. Two treatments with a diet based on maize, wheat, and soybean meal with or without 45,000 LSU(F)/kg muramidase supplementation were compared. The study found that muramidase supplementation increased daily gain and improved feed conversion ratio during the first three weeks of the growing period. From 22-42 days of age, turkeys receiving muramidase were heavier at 42 days relative to control birds. From 43-63 and 64-84 days of age, muramidase tended to increase daily gain and feed intake. Over the 84-day trial period, muramidase supplementation increased weight gain and resulted in a final heavier weight of turkeys fed a maize, wheat, and soybean meal-based diet. A secondary benefit found was that there was no difference found in the incidence and severity of footpad dermatitis.

Results

The results of the experiments indicate that muramidase supplementation can improve the performance parameters of turkeys. The improvement in performance, as indicated by the greater body weight, average daily gain and FCR, can be attributed to the ability of muramidase to hydrolyze PGN of dead bacterial cell walls. This leads to a reduction in bacterial cell debris and a subsequent improvement in gut functionality, which is crucial for efficient nutrient utilization and performance. The greater breast meat yield in turkeys fed muramidase, regardless of dose, can be attributed to the improvement in gut function, which leads to better nutrient absorption and feed utilization. The lower pododermatitis score 2, can be attributed to the ability of muramidase to reduce the bacterial cell debris covering the intestinal epithelium and maintain an effective gut environment.

Conclusion

In conclusion, muramidase supplementation improved performance, breast meat yield, feed efficiency, and additional secondary parameters, proportional to the dose in the diets. These findings are consistent with previous studies on the effect of muramidase in broilers, where it also showed positive effects on performance, nutrient digestibility, and more. Overall, this suggests that muramidase could be a valuable addition to the diets of both broilers and turkeys to improve their performances.

Table 1. Growth performance of turkey poults fed Balancius® from hatch to 126 days of age1, trial 1

Table 2. Carcass yield and cut up proportion from 130-d-old turkey poults fed Balancius® from hatch to 130 days of age1, trial 1

Table 3. Frequency of pododermatitis scores (0 to 4) from turkey poults fed Balancius® from hatch to d 56 of age. Treatments were control (T1), the T1 supplemented with 45,000 LSU/kg Balancius® from phase 1 to 6 (T2), and the T1 supplemented with 45,000 or 25,000 LSU/kg Balancius® from phases 1 to 3 or 4 to 6, respectively (T3). a-b Birds fed T2 or T3 had a greater frequency of score 1 and a lower frequency of score 2 compared with birds fed the control (P = 0.021). Trial 1.

Figure 1. Frequency of pododermatitis scores (0 to 4) from turkey poults fed Balancius® from hatch to d 56 of age. Treatments were a control (T1), the T1 supplemented with 45,000 LSU/kg Balancius® from phase 1 to 6 (T2), and the T1 supplemented with 45,000 or 25,000 LSU/kg Balancius® from phase 1 to 3 or 4 to 6, respectively (T3). a-b Birds fed T2 or T3 had a greater frequency of score 1 and lower frequency of score 2 compared with birds fed the control (P = 0.021). Trial 1.

Table 4: Performance results, trial 2

Published on

10 August 2023

Tags

  • Poultry
  • Turkey
  • Enzymes
  • Gut Health

About the Authors

Irene Eising - Product Manager, Balancius®, Animal Nutrition and Health at dsm-firmenich

Irene works as Product Manager Balancius® in the EMEA performance solutions team at dsm-firmenich Nutritional Products. She has 11 years’ experience in the animal feed industry, specializing in monogastrics and gut health solutions. Prior, she obtained experience in both the feed mill and animal additive industry. She studied at Wageningen University and Research where she obtained both her BSc and MSc in Animal Science, specializing in animal nutrition.

Carrie Walk - Senior Scientist Poultry, Animal Nutrition and Health at dsm-firmenich

Carrie is an EMEA Principal Scientist, part of the Global Innovation team, at dsm-firmenich Nutritional Products. She has 12 years of industry and academic research experience, specializing in exogenous enzymes, feed additives, nutrition, and gut health in pigs and poultry. Carrie is an author or co-author of 65 peer-reviewed papers, 6 book chapters, and editor of 2 books on exogenous enzymes in pigs and poultry. She received a BSc and MSc in Animal Science from the University of Missouri and a Ph.D. in Animal and Poultry Science from Virginia Tech.

Share

You are being redirected.

We detected that you are visitng this page from United States. Therefore we are redirecting you to the localized version.